Literature DB >> 24804749

Reply to: The importance and challenge of pediatric trials of hemophilia drugs.

Flora Peyvandi1, Frits R Rosendaal2, Brian O'Mahony3, Pier Mannuccio Mannucci4.   

Abstract

Entities:  

Mesh：

Year:  2014        PMID： 24804749     DOI： 10.1038/nm.3551

Source DB:  PubMed          Journal:  Nat Med        ISSN： 1078-8956            Impact factor:   53.440


× No keyword cloud information.
  6 in total

1.  Pediatric requirements in Europe stymie help for hemophilia.

Authors:  Flora Peyvandi; Frits R Rosendaal; Brian O'Mahony; Pier Mannuccio Mannucci
Journal:  Nat Med       Date:  2014-02       Impact factor: 53.440

2.  The importance and challenge of pediatric trials of hemophilia drugs.

Authors:  Robin Huff
Journal:  Nat Med       Date:  2014-05       Impact factor: 53.440

3.  The importance and challenge of pediatric trials of hemophilia drugs.

Authors:  Dirk Mentzer; Emilie Desfontaine; Paolo A Tomasi
Journal:  Nat Med       Date:  2014-05       Impact factor: 53.440

Review 4.  Harmonization of clinical trial guidelines for assessing the risk of inhibitor development in hemophilia A treatment.

Authors:  L M Aledort
Journal:  J Thromb Haemost       Date:  2011-03       Impact factor: 5.824

Review 5.  How I treat age-related morbidities in elderly persons with hemophilia.

Authors:  Pier M Mannucci; Roger E G Schutgens; Elena Santagostino; Evelien P Mauser-Bunschoten
Journal:  Blood       Date:  2009-10-16       Impact factor: 22.113

6.  Thirty years of hemophilia treatment in the Netherlands, 1972-2001.

Authors:  Iris Plug; Johanna G van der Bom; Marjolein Peters; Evelien P Mauser-Bunschoten; Arja de Goede-Bolder; Lily Heijnen; Cees Smit; Jeannette E F Zwart-van Rijkom; José Willemse; Frits R Rosendaal
Journal:  Blood       Date:  2004-08-12       Impact factor: 22.113
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.